MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.euf.2026.08.001

Медицинская библиотека · European urology focus · 2026

Water Vapor Thermal Therapy with Rezūm Versus Combination Pharmacotherapy for Male Lower Urinary Tract Symptoms due to Benign Prostatic Obstruction: 1-Yr Results From a Prospective, Multicenter, Pragmatic Randomized Controlled Trial (VAPEUR-RCT).

Vincendeau Sébastien, Xylinas Evanguelos, Fourmarier Marc, Galliot Ismael, Salin Ambroise, Lebdai Souhil, Olivier Jonathan, Anderson Paul, Ballereau Charles, Laclergerie Florian, Barret Eric, Misraï Vincent, Fassi-Fehri Hakim, Durand Matthieu, Mallet Richard, Franquet Quentin, Robert Grégoire, Scailteux Lucie-Marie, Beaudoint Caroline, O'Connor Patrick, Searcy Isabelle, Goodrich Kathryn, Cornu Jean-Nicolas, Mathieu Romain

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

The VAPEUR randomized controlled trial compared Rezūm water vapor thermal therapy (WVTT) with combination pharmacotherapy (CP; alpha-blockers plus 5-alpha-reductase inhibitors) in sexually active men with symptomatic benign prostatic obstruction (BPO).

METHODS

Overall, 151 men were randomized to WVTT (n = 75) or CP (n = 76). Primary endpoints changed from baseline to 1 yr in the International Prostate Symptom Score (IPSS) and Male Sexual Health Questionnaire (MSHQ) score. Secondary endpoints included surgical/medical treatment for recurring symptoms, ≥4 points IPSS worsening (ΔIPSS ≥4), and catheterization beyond 90 d post-procedure.

KEY FINDINGS AND LIMITATIONS: At 1 yr, IPSS improvement was greater with WVTT than CP (mean difference -4.6 points; 97.5% confidence interval [CI] -7.6 to -1.6; p < 0.001), with mean improvements of 10.8 ± 6.8 versus 6.2 ± 7.7 points, respectively. MSHQ scores remained stable with WVTT (+1.1 ± 16.9) and CP (-5.2 ± 16.4). Superiority in preserving sexual function was not demonstrated with multiple imputation. Quality‑of‑life (QoL) improvement was greater with WVTT (-2.7 ± 1.8 vs -1.8 ± 2.0; p = 0.01). WVTT resulted in lower rates of surgical retreatment (1.3% vs 9.2%), ΔIPSS ≥4, (2.7% vs 13%) and post-90 d catheterization (0% vs 1.3%), but higher pharmacological retreatment (12% vs 1.3%; combined: hazard ratio = 0.52, CI 0.25-1.1, p = 0.08). Treatment‑related adverse events (AEs) were more frequent with WVTT (40% vs 28%; serious AEs, 12% vs 1.3%), largely procedure‑related; at 1 yr, 93% were resolved in WVTT versus 60% (25/42) in CP.

CONCLUSIONS AND CLINICAL IMPLICATIONS: At 1 yr, WVTT provides superior symptom relief and greater QoL improvement versus CP, while preserving sexual function. These findings support WVTT as an effective alternative to CP.

Для цитирования: Vincendeau Sébastien, Xylinas Evanguelos, Fourmarier Marc, Galliot Ismael, Salin Ambroise, Lebdai Souhil, Olivier Jonathan, Anderson Paul, Ballereau Charles, Laclergerie Florian, Barret Eric, Misraï Vincent, Fassi-Fehri Hakim, Durand Matthieu, Mallet Richard, Franquet Quentin, Robert Grégoire, Scailteux Lucie-Marie, Beaudoint Caroline, O'Connor Patrick, Searcy Isabelle, Goodrich Kathryn, Cornu Jean-Nicolas, Mathieu Romain. Water Vapor Thermal Therapy with Rezūm Versus Combination Pharmacotherapy for Male Lower Urinary Tract Symptoms due to Benign Prostatic Obstruction: 1-Yr Results From a Prospective, Multicenter, Pragmatic Randomized Controlled Trial (VAPEUR-RCT).. European urology focus. 2026. DOI: 10.1016/j.euf.2026.08.001.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.